Ovid Therapeutics to Present at the 12th International Epileps...
NEW YORK, May 24, 2019 /PRNewswire-AsiaNet/ -- -- First scientific presentation of OV-935 (TAK-935) safety and tolerability data in developmental and epileptic encephalopathies from the Phase 1b/2a clinical trial -- Study met primary safety and tolerability endpoints and showed initial evi...
Authors: LATEST ASIANET NEWS RELEASES